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ABSTRACT 
This study had been performed to investigate the anatomic and functional outcomes of nepafenac 0.1% 
therapy in acute central serous chorioretinopathy (CSC). The medical records of 30 patients with acute CSC 
were reviewed for a total of 31 eye charts. Seventeen eye records of 16 patients who were treated with 
topical nepafenac 0.1% three times daily for four weeks and continued until complete resolution of 
subretinal fluid were appraised. Fourteen patients with acute CSC (a total of 14 eye records) who did not 
receive treatment served as the control group also had been recorded. The proportion of eyes with 
complete resolution of subretinal fluid, serial changes in the mean best corrected visual acuity (BCVA), and 
the mean central foveal thickness (CFT) at 6 months of therapy were the outcomes measured. Mean age 
was 42.6±8.2 years in the treatment group and 41.1±7.1 years in the control group (p=0.85). At 6 months, 
14 eyes (82.3%) in the treatment group and 6 eyes (42.8%) in the control group revealed a complete 
resolution in the subretinal fluid (p=0.02). In the treatment group, mean BCVA (LogMAR) significantly 
improved from 0.19±0.17 at baseline to 0.09±0.12 at 6 months (p=0.01). In the control group, mean BCVA 
(LogMAR) was 0.13±0.14 at baseline and decreased to 0.1±0.11 at 6 months (p=0.28). In the treatment 
group, mean CFT was 349±115 µm at baseline and significantly improved to 221±95 µm at 6 months 
(p<0.01). In the control group, mean CFT declined from 391±138 µm at baseline to 301±125 µm at 6 
months (p=0.06). No treatment-related ocular or systemic side effects were observed. In conclusion, 
nepafenac 0.1% has the potential to treatment acute CSC. Further trials are warranted to study its safety 
and efficacy for this disease. 
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INTRODUCTION 
Central serous chorioretinopathy (CSC) is characterized 
by a serous detachment of the neurosensory retina at 
the posterior pole, which is caused by active retinal 
pigment epithelial (RPE) leakage (1,2). The disease has a 
favorable natural course with the spontaneous resolution 
of the neurosensorial detachment in association with 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2013 Winter;2(4)  
 
97 NEPAFENAC IN TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY 
improvement of visual function. However, it is very 
difficult to predict the prognosis of CSC, and in some 
cases, progressive visual loss may be seen (3,4). Thus, an 
intervention should be considered in CSC patients prior 
disruption of retinal layers. Gilbert et al. demonstrated 
that 51% of untreated patients experienced a single 
resolving attack, and 49% of them had a recurrent or 
chronic clinical course (5). Although the exact 
pathophysiology of CSC has not been clearly elucidated, 
the primary abnormality leading to RPE disruption and 
leakage is thought to be increased choroidal permeability 
(6). Studies using different imaging techniques have 
revealed the possible causes of abnormal permeability of 
the inner choroid. Ischemia and inflammation might lead 
to exudative changes within the choroid and the 
subsequent changes at the RPE (6-8). 
  Nepafenac is a topical nonsteroidal anti-inflammatory 
prodrug that rapidly penetrates the cornea and is 
deaminated to form the active metabolite amfenac by 
intraocular hydrolases in the ocular tissues, including the 
ciliary body epithelium, retina, and choroid (9). Its 
bioactivation enhances intraocular penetration at the 
target sites and provides optimal distribution and longer 
duration in the cornea, iris, ciliary body, retina, and 
choroid (10). The effectiveness of nepafenac has been 
revealed in inflammatory diseases affecting the posterior 
segment of the eye such as uveitic and pseudophakic 
chronic cystoid macular edema (11). 
  The purpose of this study was to evaluate the effect of 
nepafenac 0.1% in patients with acute CSC, and it was 
hypothesized that inflammatory process might be 
involved in the pathogenesis of the disease.  
 
METHODS 
The data were collected from medical records of 
consecutive patients who were admitted with CSC to the 
Retina Clinic of Beyoglu Eye Training and Research 
Hospital from December 2010 to July 2012. The 
treatment group comprised those with eyes treated by 
topical nepafenac 0.1%, and the control group comprised 
those without treatment. Approval for data collection 
and analysis was obtained from the ethics committee of 
the hospital. The study methodology was designed in 
accordance with the tenets of the Declaration of Helsinki. 
Written informed consent was obtained from the 
patients accordingly.All patients had compromised visual 
acuity caused by acute CSC diagnosed on fundus 
examination; fluorescein angiography (FA); indocyanine 
green angiography (ICGA) (Heidelberg Retinal 
Angiograph, Heidelberg Engineering, Heidelberg, 
Germany); and optical coherence tomography (OCT) 
(Stratus Tomographer, Model 3000; Carl Zeiss 
Ophthalmic Systems, Dublin, CA). All eyes had one or 
more focal areas of active angiographic leakage on FA 
and/or abnormal dilated choroidal vasculature and 
hyperpermeability on ICGA with neurosensory retinal 
detachment involving the fovea on OCT. Patients who 
received former treatment for CSC or had evidence of 
choroidal neovascularization or other maculopathy on 
examination and patients who had known or suspected 
hypersensitivity to any component of study medication 
or had any ocular pathology preventing nepafenac 
treatment were excluded.  
  A complete ophthalmic examination including best 
corrected visual acuity (BCVA) testing with standardized 
refraction using Early Treatment Diabetic Retinopathy 
Study (ETDRS) charts, applanation tonometry, and fundus 
examination with a 90 diopters indirect lens following 
mydriasis was performed at baseline and at 1, 3, and 6 
months of therapy.  
  Drug therapy was started when there was no evidence 
of resolution in subretinal fluid after two consecutive 
monthly visits in the treatment group. All patients in this 
group received topical nepafenac 0.1% (Nevanac; Alcon 
Laboratories, Inc., Fort Worth, TX) 3 times in a day for at 
least 4 weeks and continued until subretinal fluid 
resolved.  
  The primary outcome measure was the proportion of 
eyes with complete resolution of subretinal fluid at 6 
months of therapy. Secondary outcome measures were 
the serial changes in mean BCVA and mean central foveal 
thickness (CFT). 
  Visual acuity was converted to a logarithm of the 
minimum angle of resolution (logMAR) for statistical 
analysis. Numerical variables were summarized using 
means and standard deviations while categorical 
variables were summarized using frequencies and 
percentages. The Mann-Whitney U test or chi-square test 
was used to compare variables between the two groups, 
and the Wilcoxon test was used to compare variables 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2013 Winter;2(4)  
 
98 NEPAFENAC IN TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY 
within the groups. The statistical evaluation was 
performed using SPSS (Version 16.0, SPSS Inc., Chicago, 
IL, USA). A p value of less than 0.05 was considered to be 
statistically significant. 
 
RESULTS 
A total of 31 eyes from 30 patients with acute CSC were 
included in this retrospective, interventional, and 
controlled study. Seventeen eyes from 16 male patients 
with acute CSC were treated by topical 0.1% Nepafenac. 
The control group consisted of 14 eyes from 14 patients 
(11 male, 3 female) with acute CSC. The mean age was 
42.6±8.2 years in the treatment group and 41.1±7.1 
years in the control group (p=0.85). The demographic 
data and clinical findings of the two groups are shown in 
Table 1. 
 
Table 1.Baseline demographics and clinical findings of the treatment 
group and control group. 
 Treatment 
group  
(eyes n:17) 
Control 
group  
(eyes n:14) 
p 
value 
Mean age ±SD
a
, years 
(range) 
42.6±8.2 
(26-59) 
41.1±7.1 
(29-52) 
0.85 
Gender, male/female 
(male %) 
16/0 (100%) 11/3 
(78.5%) 
0.08 
Mean baseline 
BCVA
b
±SD, logMAR
c
 
(range) 
0.19±0.15 
(0.0-0.52) 
0.13±0.14 
(0.0-0.4) 
0.29 
Mean baseline 
CFT
d
±SD, microns 
(range) 
349±115 
(189-548) 
391±138 
(236-683) 
0.08 
Number of 
recurrences before 
therapy±SD (range) 
1.5±0.7 
(1-3) 
1.2±0.4 
(1-2) 
0.46 
aSD: Standard deviation; bBCVA: Best corrected visual acuity; clogMAR: 
Logarithm of the minimum angle of resolution; dCFT: Central macular 
thickness 
 
  At six months, complete resolution of macular 
subretinal fluid was observed in 14 of 17 eyes (82.3%) in 
the treatment group and 6 of 14 eyes (42.8%) in the 
control group (p=0.02). Three eyes in the treatment 
group and 8 eyes in the control group had no resolution 
of serous macular detachment, and these 11 eyes were 
assigned to have treatment with photodynamic therapy 
(PDT) or laser photocoagulation. 
  In the treatment group, the mean baseline BCVA 
(LogMAR) changed from 0.19±0.17 to 0.16±0.15 at one 
month, 0.11±0.14 at 3 months, and 0.09±0.12 at 6 
months (p=0.39, p=0.08, p=0.01, respectively). In the 
treatment group, there was a significant difference in 
mean BCVA at 6 months compared to the baseline. In the 
control group, the mean baseline BCVA (LogMAR) 
changed from 0.13±0.14 to 0.11±0.13 at 1 month, 
0.11±0.12 at 3 months, and 0.1±0.11 at 6 months 
(p=0.43, p=0.39, p=0.28, respectively). In the control 
group, mean BCVA did not illustrate a significant 
difference throughout the follow-up period. No 
significant difference was observed between the two 
groups at baseline and at 1, 3, and 6 months (p=0.29, 
p=0.33, p=0.97, p=0.89, respectively).  
 
 
Figure 1. Change in best corrected visual acuity (logMAR) from baseline 
and to the 1-, 3-, and 6-month follow-up in the treatment group and 
control group.  
 
 
Figure 2. Change in central foveal thickness (µm) from baseline and to 
the 1-, 3-, and 6-month follow-up in the treatment group and control 
group. 
 
  In the treatment group, the mean baseline CFT 
significantly decreased from 349±115 µm to 257±120 µm 
at 1 month, 248±101 µm at 3 months, and 221±95 µm at 
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6 months (p<0.01 for all comparisons). In the control 
group, the mean baseline CFT decreased from 391±138 
µm to 320±132 µm at 1 month, 316±130 µm at 3 
months, and 301±125 µm at 6 months. However, the 
mean baseline CFT did not change significantly compared 
to the baseline (p=0.08, p=0.07, p=0.06, respectively). No 
significant difference was observed between the two 
groups at baseline and at 1, 3, and 6 months (p=0.37, 
p=0.13, p=0.12, p=0.09, respectively). Furthermore, no 
ocular or systemic side effects were observed in the 
treatment group during the follow-up period. 
 
DISCUSSION 
In the present study, the results demonstrated that 
topical nepafenac 0.1% therapy has promising results for 
the treatment of CSC. This disease generally affects 
young people who are of working age, and visual 
symptoms such as blurred vision, metamorphopsia, 
micropsia, dyschromatopsia, central scotoma, and 
hypermetropization might interfere with their daily 
activities considerably. The disease usually resolves 
spontaneously within three months after onset (12). 
Currently there is no standard therapy for acute CSC, 
even though there have been many treatment modalities 
studied including laser photocoagulation, PDT, and 
pharmacological agents (13-21). Heretofore, laser 
photocoagulation of the extrafoveal leaking points has 
been attempted to treat acute CSC. Although laser 
photocoagulation may shorten the time of resolution of 
serous detachment, it does not have any beneficial effect 
on the final VA. Additionally, photocoagulation may 
induce iatrogenic choroidal neovascularization and/or 
damage to the foveal photoreceptors (13). Lately, PDT 
with verteporfin has begun to be utilized for treatment of 
acute CSC. Although PDT may be beneficial for the 
treatment of acute CSC by decreasing the 
choroidalhyperpermeability, it also may trigger 
alterations on the structure of choroidal vasculature (14). 
The patients with acute CSC usually have relatively good 
baseline VA; therefore, it is imperative to keep in mind 
the potential adverse events caused by PDT. Chan et al. 
treated 63 patients with acute CSC with half-dose 
verteporfin PDT or placebo PDT in an attempt to 
demonstrate the safety of PDT (22). Subsequent to a 
follow-up time of 12 months, 94% of the eyes exhibited 
complete resolution of serous macular detachment in 
the half-dose PDT group versus only 57% of the eyes in 
the placebo group. The results of former studies revealed 
that half-dose verteporfin PDT is an effective treatment 
option for acute CSC. Despite the encouraging results of 
PDT with half-dose verteporfin, the cost of verteporfin 
may limit the use of PDT in treating acute CSC.  
  Treatment of acute CSC with intravitreal injections of 
anti-VEGF agents has variable outcomes (15,16). Lim et 
al. demonstrated that VEGF and IL-8 levels were not 
elevated in the aqueous humor and plasma of CSC 
patients compared with a healthy group (23). In light of 
these findings, further investigations are required with 
regard to the mechanism and results of intravitreal anti-
VEGF treatment in acute CSC.   
  Pikkel et al. demonstrated limited recovery in CSC 
patients with acetazolamide (17). In addition, its use is 
limited because of its potential side effects. It has been 
proposed that corticosteroid antagonists could be used 
for treatment of acute CSC such as mifepristone and 
ketoconazole. However, trials with these drugs have 
proven unsuccessful (18,19). Metoprololand propranolol, 
another treatment strategy with adrenergic receptor 
inhibitors, should be used very cautiously because of its 
significant side effects and potential morbidity (20,21). 
  Former studies have suggested that choroidal ischemia 
and/or inflammation caused by nitric oxide, 
prostaglandins, and free radicals might be involved in the 
pathogenesis of CSC (6-8). Consequently, medications 
such as antioxidants or anti-inflammatories might be 
effective in decreasing the choroidal leakage especially in 
the early stages of CSC. Ratanasukon et al. administrated 
either high-dose antioxidant tablet or placebo tablets for 
3 months or until complete resolution of subretinal fluid 
(24). An additional treatment with laser or PDT was 
performed if any fluorescein leakage persisted following 
3 months. They found no statistical difference in terms of 
VA and CFT between the groups at the end of the third 
month, but the patients treated with high-dose 
antioxidants revealed less fluorescein leakage. In the 
present study, the results demonstrated that topical 
nepafenac 0.1% therapy has promising results for the 
treatment of CSC. Treatment resulted in complete 
resorption of subretinal fluid in the macula in 82.3% of 
eyes in the treatment group versus 42.8% in the control 
group. Chan et al. demonstrated that complete 
resorption of subretinal fluid occurred in only 57% of 
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eyes with acute CSC in the control group of one study at 
6 months (25). We propose that our treatment regimen 
is superior to the natural resolution of the disease. In 
terms of its safety profile, the use of nepafenac 0.1% is 
promising because neither ocular toxicity nor systemic 
adverse effects were observed.  
  The limitations of this study were the small number of 
patients and the short follow-up duration. The actual role 
of nepafenac in treating acute CSC needs to be further 
investigated in randomized controlled clinical trials with a 
longer follow-up and with an adequate number of 
patients to determine the efficacy of the drug. 
  In conclusion, the present study suggests that topical 
treatment with nepafenac 0.1% might be an efficient 
therapeutic option instead of conservative management 
for active working patients who suffer from impairment 
of visual function. We found that topical nepafenac 0.1% 
therapy was effective in treating acute CSC, leading to 
visual improvement and resorption of subretinal fluid in 
most of the patients. Since this study was conducted only 
for the acute stage of CSC after less than 3 months of 
onset, we do not suggest the use of this therapy in place 
of conventional methods for the complicated or chronic 
CSC. 
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